HIV cure research in the time of COVID-19 - Antiretroviral therapy treatment interruption trials: A discussion paper
| Autor: | Simon Collins, Steven G. Deeks, Ole Schmeltz Søgaard, Jerome Amir Singh, D Kelly, John Frater, Marina Caskey, L Vanderkerckhove, Sarah Fidler, Sharon R Lewin |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Epidemiology Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Immunology Human immunodeficiency virus (HIV) Context (language use) medicine.disease_cause Microbiology 03 medical and health sciences Viewpoint 0302 clinical medicine Virology Pandemic medicine 030212 general & internal medicine Intensive care medicine business.industry Analytical treatment interruption (ATI) COVID-19 SARS-CoV-2 HIV cure Public Health Environmental and Occupational Health Antiretroviral therapy QR1-502 Clinical trial 030104 developmental biology Infectious Diseases Treatment interruption Public aspects of medicine RA1-1270 business |
| Zdroj: | Journal of Virus Eradication, Vol 7, Iss 1, Pp 100025-(2021) Journal of Virus Eradication Fidler, S, Lewin, S, Deeks, S, Sogaard, O S, Vanderkerckhove, L, Collins, S, Kelly, D, Singh, J, Caskey, M & Frater, J 2021, ' HIV cure research in the time of COVID-19-Antiretroviral therapy treatment interruption trials : A discussion paper ', Journal of virus eradication, vol. 7, no. 1, 100025 . https://doi.org/10.1016/j.jve.2020.100025 |
| ISSN: | 2055-6640 |
| Popis: | This discussion paper addresses the safety of HIV cure studies, particularly those involving stopping antiretroviral therapy, known as an analytic treatment interruption (ATI) in the context of the SARS-CoV-2 pandemic. More than 30 studies listed on ClinicalTrials.gov include an ATI and many others were planned to begin over the next 12 months but most were halted due to the COVID-19 pandemic. We consider the ethics, risks and practical considerations to be taken into account before re-opening HIV cure clinical trials, noting the specific risks of ATI in the context of circulating SARS-CoV-2. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|